MeiraGTx Reports Positive 3-Year Data for AAV-hAQP1 in Xerostomia, Projecting Billions in Peak Revenue
MGTX has more than doubled off its 52-week low of $4.55.
Summary
MeiraGTx announced highly positive three-year clinical data for its AAV-hAQP1 gene therapy in radiation-induced xerostomia, demonstrating sustained efficacy and safety, with the company projecting multi-billion dollar peak annual revenue potential.
Key Events · Product Development and Regulatory · MGTX
-
Positive 3-Year Clinical Data
AAV-hAQP1 gene therapy showed sustained safety and efficacy in treating radiation-induced xerostomia over three years in the Phase 1 AQUAx study.
-
Sustained Efficacy Demonstrated
Clinically meaningful improvements in Xerostomia Questionnaire (XQ) scores and normalization of Unstimulated Whole Saliva Flow Rate (UWSFR) were maintained for 36 months after a single treatment.
-
Significant Commercial Opportunity
The company estimates peak global annual revenue potential of up to $3.7 billion for AAV-hAQP1, addressing a large unmet medical need.
-
Potential First-in-Class Therapy
AAV-hAQP1 is positioned as a potential first-in-class, disease-modifying therapy for severe, lifelong radiation-induced xerostomia.
Analysis · MGTX · Life Sciences
This 8-K formalizes the highly positive three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1, a gene therapy for radiation-induced xerostomia. The data confirms the therapy's safety and remarkable durability, with clinically meaningful improvements in both patient-reported symptoms (XQ scores) and objective measures (saliva flow rate) maintained for 36 months after a single treatment. The company's projection of up to $3.7 billion in peak global annual revenue, significantly exceeding its current market capitalization, highlights the transformative commercial opportunity for this potential first-in-class, disease-modifying therapy. This de-risks a key pipeline asset and provides a strong long-term growth outlook, reinforcing investor confidence. This news was previously announced via a press release today.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGTX was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $916.3M. The 52-week trading range was $4.55 to $11.85. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.